IARC Monographs Volume 108: Some Drugs and Herbal Products – Methylene Blue, Section 1 Exposure Data (technical products and impurities) (2016)

Peer-Reviewed Study · IARC Working Group on the Evaluation of Carcinogenic Risks to Humans (WHO) · 2016

IARC Working Group on the Evaluation of Carcinogenic Risks to Humans (WHO), 2016: WHO cancer agency monograph section describing methylene blue's identity, technical forms and named impurities, including that it forms double salts and that commercial material is typically sold as a hydrate. It documents the azure dye impurities and the pharmacopoeial specifications.

Description: Dark green crystals or crystalline powder with bronze lustre, odourless, stable in air, deep blue solution in water or alcohol, forms double salts

IARC Working Group on the Evaluation of Carcinogenic Risks to Humans (WHO), 2016: WHO cancer agency monograph section describing methylene blue's identity, technical forms and named impurities, including that it forms double salts and that commercial material is typically sold as a hydrate. It documents the azure dye impurities and the pharmacopoeial specifications. Official monograph chapter (record field transcription). Issuer: IARC/WHO. Content: impurities named as azure A, azure B and azure C (with structures); 'forms double salts' in the physical description; commercial methylene blue 'typically sold as the hydrate, but is sometimes incorrectly presented as the trihydrate'; trade names include urolene blue; 'Specifications for methylene blue are published in several official pharmacopoeias'. Also records the FDA 2011 serotonin warning and an oral paediatric malaria dose of 20 mg/kg in Burkina Faso. Note: this document does not analyse heavy-metal contamination of industrial grade; it lists the dye-related impurities, which are different from lead/arsenic/mercury. Also filed as MTF-53, MTF-55 (claims C10, C13, C14). Study type: review.